Homocysteinemia: Role in vascular disease;Homocysteinemie: Role en pathologie vasculaire

Presse Medicale

Volumn 29, Issue 13, 2000, Pages 737-741

  Conri, C ^a,b   Constans, J ^a   Parrot, F ^b   Skopinski, S ^a   Cipriano, C ^a  

^a HÔPITAL PELLEGRIN   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE; HOMOCYSTEINE;

ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HOMOCYSTINURIA; HUMAN; REVIEW; ARTICLE; BLOOD; BRAIN INFARCTION; CORONARY ARTERY DISEASE; RISK FACTOR; VASCULAR DISEASE;

CEREBRAL INFARCTION; CORONARY DISEASE; HOMOCYSTEINE; HUMANS; RISK FACTORS; VASCULAR DISEASES;

EID: 0034620848     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. McCully KS. Vascular pathology of homocysteinemia : implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969 ; 56:111-28.
2. Hankey GJ, Eikelboom JN. Homocysteine and vascular disease. Lancet 1999 ; 354:407-13.
3. Finkelstein JD. The metabolism of homocysteine : pathways and regulation. Eur J Pediatr 1998 ; 157(suppl 2):S40-4.
4. Mudd SH, Skovby F, Levy HL et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985 ; 37:1-31.
5. Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia : a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988 ; 43:414-21.
6. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease : a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995 ; 10:111-13.
7. Malinow MR, Nieto FJ, Kruger WD et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler Thromb Vasc Biol 1997 ; 17:1157-62.
8. Jacques PF, Boston AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996 ; 93:7-9.
9. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993 ; 270:2693-8.
10. Bostom AG, Lathrop L. Homocysteinemia in end-stage renal disease : prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997 ; 52:10-20.
11. Hussein WI, Green R, Jacobsen DW, Faiman C. Normalization of hyperhomocysteinemia with L-Thyroxine in hypothyroïdism. Ann Int Med 1999 ; 131:348-51.
12. Dierhes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999 ; 354:219-20.
13. Malinow MR, Duel PB, Hess DL et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998 ; 338:1009-15.
14. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease : a critical review of the epidemiologic evidence. Ann Int Med 1999 ; 131:363-75.
15. Wald MJ, Watt HC, Law MR, Weir DG, Partin J Mc, Scott JM. Homocysteine and ischemic heart disease. Results of prospective study with implications regarding prevention. Arch Intern Med 1998 ; 158:862-7.
16. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocystein, related genetic polymorphisms, and B vitamins. The atherosclerosis risk in communities (ARIC) study. Circulation 1998 ; 98:204-10.
17. Nygard D, Nordrehang JE, Refsum H, Veland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997 ; 337:330-6.
18. Stampfer MJ, Malinow MR, Willet WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992 ; 268:877-81.
19. Arnesen E, Refsum H, Bonaa KJ, Veland PM, Forde OH, Nordrehang JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995 ; 24:704-9.
20. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995 ; 346:1395-8.
21. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willet WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery by pass surgery. Am J Cardiol 1997 ; 79:799-801.
22. Verhoef P, Hennekens CH, Malinow MR, Willet WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994 ; 25:1924-30.
23. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997 ; 28:1739-43.
24. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995 ; 26:795-800.
25. Hopkins PN, Wu LL, Wu J et al. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995 ; 15:1314-20.
26. Dalery K, Lussier-Cacan S, Selhub J, Davignon J, Latour Y Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects : relation with vitamins B12, B6, pyridoxa phosphate, and folate. Am J Cardiol 1995 ; 75:1107-11.
27. Robinson K, Mayer EL, Miller DP et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995 ; 92:2825-30.
28. Malinow MR, Ducimetiere P, Luc G et al. Plasma homocyst(e)ine levels and graded risk for myocardial infarction findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996 ; 126:27-34.
29. Graham IM, Daly LE, Refsum HM et al. Plasma homocystein as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997 ; 277:1775-81.
30. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease : probable benefit of increasing folic acid intake. JAMA 1995 ; 274:1049-57.
31. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998 ; 338:1042-50.
32. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998 ; 158:2101-16.
33. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inaemia, factor V Leiden, and risk of future venous thromoembolism. Circulation 1997 ; 95:1777-82
34. D'angelo A, Selbub J. Homocysteine and thrombotic disease. Blood 1997 ; 90:1-11.
35. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990 ; 75:895-901.
36. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991 ; 88:1906-14.
37. Fryer RH, Wilson BD, Gubler GM, Fitzerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis induces tissue factor activity in endothelial cells. Arterioscl Thromb 1997 ; 13:1327-33.
38. Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle growth by homocysteine : a link to atherosclerosis. Proc Natl Acad Sci USA 1994 ; 91:6369-73.
39. Wang H, Yoshirumi M, Laik et al. Inhibition of growth and P21 methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997 ; 272:25380-5.
40. Poddar R, Sivasubramanian N, Robinson K, Jacobsen DW. Homocysteine promotes expression of monocyte chemoattractant protein 1 and interleukin 8 in human aortic endothelial cells. Circulation 1997 ; 96:286.
41. Tawakol A, Omlard T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependant vasodilatation in humans. Circulation 1997 ; 95:1119-21.
42. Chambers JC, McGregor A, Jeanmarie J, Kooner JS. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998 ; 351:36-7.
43. Constans J, Blann A, Resplandy F et al. Endothelial dysfunction during acute methionine load in hyperhomocysteinemic patients. Atherosclerosis 1999 ; 147:411-13.
44. LOSCALZO J. The oxidant stress of hyperhomocyst(e)inaemia. J Clin Invest 1996 ; 98:5-7.
45. Malinow MR, Nieto FJ, Szklo M, Chambless LE, BONG G. Carotid arterial intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993 ; 87:1107-13.
46. Montalescot G, Ankri A, Chadefaux-Vekemans B et al. Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. Int J Cardiol 1997 ; 60:295-300.
47. Van Den Berg M, Stehouwer CD, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996 ; 16:165-71.
48. Homocysteine lowering trialist's collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998 ; 316:894-8.
49. Chasan-Taber L, Selhub J, Rosenberg IH et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996 ; 15:136-43.
50. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998 ; 98:196-9.
51. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997 ; 349:397.